Background
CA 19-9 antibody reacts strongly positive with most tumour cell lines of gastrointestinal carcinoma including adenocarcinoma of the stomach, intestine, and pancreas. Positive reactivity was also found in transitional cell carcinoma of the bladder, adenocarcinoma of the endometrium and the gallbladder as well as in papillary carcinoma of the thyroid glands. Last but not least positive reactivity of lung carcinoma must be mentioned (adenocarcinoma, bronchio-alveolar carcinoma, squamous epithelial carcinoma, and SCLC). Sialyl Lewis a antigen is an oncofetal antigen, which appears during early development of the gastrointestinal tract. After birth it is still detectable in ductus and secretion of intestinal glands, respiratory and reproductive tract. In normal tissue Sialyl Lewis a (CA 19-9) is found in ductal epithelia of the breast, kidney, salivary glands, lung, colon, bile duct, liver, pancreas and prostate gland. Sialyl Lewis a antigen (Cancer Antigen CA 19-9).

Source

Immunogen: Immunodiffusion precipitate of ovarian cystic mucins with NS19-9-antibody

Product
Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.

Purification Method: Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.

Secondary Reagents: As secondary reagents we recommend the use of biotinylated anti-mouse IgM antibody (Art. No. BA-2020) in combination with streptavidin conjugates or ABC systems.

Concentration: 50 µg/ml

Specificity

Species Reactivity: Human

Applications
ELISA, IRMA, IHC (cryostat and paraffin sections)

Incubation Time: 60 min at RT

Working Concentration: (liquid conc.) 1:10 - 1:50

Pre-Treatment: In paraffin section no pre-treatment is required, however heat induced antigen retrieval may improve the staining. Each laboratory should select it's own optimum staining and pre-treatment conditions.

Positive Control: Colon carcinoma

Storage
2-8°C

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.

References
1. Gatalica Z., and Miettienen M. (1994) Distribution of carcinoma antigens CA 19-9 and CA 15-3: an immunohistochemical study of 400 tumors. Appl. Immunohistochem. 2(3); 205ff. 2. Tomazic A., and Pegan V. (2000) Preoperative staging of periampullar cancer with US, CT, EUS and CA 19-9. Hepatogastroenterol. 47(34); 1135-1137. 3. Tabata T., Takeshima N., Tanaka N., Hirai Y., and Hasumi K. (2000) Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. Tumour Biol. 21(6); 375-380. 4. Dalgleish A.G. (2000) Tumour markers in malignancies. CA19.9 is useful in several cancers. B.M.J. 321(7257); 380

Safety Datasheet(s) for this product: